Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 195-203

  Domchek, Susan M ^a   Friebel, Tara M ^b   Garber, Judy E ^c   Isaacs, Claudine ^d   Matloff, Ellen ^e   Eeles, Rosalind ^f   Evans, D Gareth ^g   Rubinstein, Wendy ^h   Singer, Christian F ⁱ   Rubin, Stephen ^a   Lynch, Henry T ^j   Daly, Mary B ^k   Weitzel, Jeffrey ^l   Ganz, Patricia A ^m   Pichert, Gabriella ⁿ   Olopade, Olufunmilayo I ^o   Tomlinson, Gail ^p   Tung, Nadine ^q   Blum, Joanne L ^r   Couch, Fergus ^s   Rebbeck, Timothy R ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e YALE UNIVERSITY   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁱ UNIVERSITY OF VIENNA   (Austria)

^j CREIGHTON UNIVERSITY   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ GUY S HOSPITAL   (United Kingdom)

^o UNIVERSITY OF CHICAGO   (United States)

^p UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^q BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^r BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^s Mayo Clinic   (United States)

more..

Author keywords

BRCA1; BRCA2; Hereditary ovarian cancer; Prophylactic Surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; OCCULT CANCER; OVARY CANCER; PAPILLARY CARCINOMA; PARITY; PERITONEUM CANCER; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; EUROPE; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NORTH AMERICA; OVARIAN NEOPLASMS; OVARIECTOMY; PREVALENCE; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77957723169     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0799-x     Document Type: Article

References (34)

1. A Eisen J Lubinski J Klijn P Moller HT Lynch K Offit B Weber T Rebbeck SL Neuhausen P Ghadirian, et al. 2005 Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study J Clin Oncol 23 30 7491 7496 10.1200/JCO.2004.00.7138 16234515
2. M Robson K Offit 2007 Clinical practice. Management of an inherited predisposition to breast cancer N Engl J Med 357 2 154 162 1:CAS:528: DC%2BD2sXnslSjsbk%3D 10.1056/NEJMcp071286 17625127
3. TR Rebbeck ND Kauff SM Domchek 2009 Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2 80 87 1:CAS:528:DC%2BD1MXhtVehsbo%3D 10.1093/jnci/djn442 19141781
4. SM Domchek TM Friebel SL Neuhausen T Wagner G Evans C Isaacs JE Garber MB Daly R Eeles E Matloff, et al. 2006 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 223 229 1:CAS:528:DC%2BD28XitVeitLs%3D 10.1016/S1470-2045(06)70585-X 16510331
5. WH Parker MS Broder E Chang D Feskanich C Farquhar Z Liu D Shoupe JS Berek S Hankinson JE Manson 2009 Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study Obstet Gynecol 113 5 1027 1037 19384117
6. TR Rebbeck T Friebel T Wagner HT Lynch JE Garber MB Daly C Isaacs OI Olopade SL Neuhausen L van 't Veer, et al. 2005 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 23 31 7804 7810 1:CAS:528:DC%2BD2MXht1Cqs7nE 10.1200/JCO.2004.00.8151 16219936 Epub 2005 Oct 7811
7. A Eisen J Lubinski J Gronwald P Moller HT Lynch J Klijn C Kim-Sing SL Neuhausen L Gilbert P Ghadirian, et al. 2008 Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 19 1361 1367 1:CAS:528:DC%2BD1cXht1Sitb7I 10.1093/jnci/djn313 18812548
8. ML Carcangiu B Peissel B Pasini G Spatti P Radice S Manoukian 2006 Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature Am J Surg Pathol 30 10 1222 1230 10.1097/01.pas.0000202161.80739.ac 17001151
9. KH Lu JE Garber DW Cramer WR Welch J Niloff D Schrag RS Berkowitz MG Muto 2000 Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy J Clin Oncol 18 14 2728 2732 1:CAS:528: DC%2BD3cXls12iu7g%3D 10894872
10. ND Kauff JM Satagopan ME Robson L Scheuer M Hensley CA Hudis NA Ellis J Boyd PI Borgen RR Barakat, et al. 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 21 1609 1615 10.1056/NEJMoa020119 12023992
11. K Leeper R Garcia E Swisher B Goff B Greer P Paley 2002 Pathologic findings in prophylactic oophorectomy specimens in high-risk women Gynecol Oncol 87 1 52 56 10.1006/gyno.2002.6779 12468342
12. TR Rebbeck HT Lynch SL Neuhausen SA Narod L Van't Veer JE Garber G Evans C Isaacs MB Daly E Matloff, et al. 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 21 1616 1622 10.1056/NEJMoa012158 12023993
13. A Finch M Beiner J Lubinski HT Lynch P Moller B Rosen J Murphy P Ghadirian E Friedman WD Foulkes, et al. 2006 Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation JAMA 296 2 185 192 1:CAS:528:DC%2BD28XmvFeiu7w%3D 10.1001/jama.296.2.185 16835424
14. RI Olivier LA Lubsen-Brandsma H van Boven M van Beurden 2005 Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecol Oncol 96 2 439 443 10.1016/j.ygyno.2004.10.017 15661233
15. DG Evans R Clayton P Donnai A Shenton F Lalloo 2009 Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk Eur J Hum Genet 17 11 1381 1385 10.1038/ejhg.2009.60 19367322
16. HM Klaren LJ van't Veer FE van Leeuwen MA Rookus 2003 Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation J Natl Cancer Inst 95 13 941 947 10.1093/jnci/95.13.941 12837830
17. S Wacholder 2004 Bias in intervention studies that enroll patients from high-risk clinics J Natl Cancer Inst 96 16 1204 1207 10.1093/jnci/djh229 15316055
18. ND Kauff SM Domchek TM Friebel ME Robson J Lee JE Garber C Isaacs DG Evans H Lynch RA Eeles, et al. 2008 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 1331 1337 10.1200/JCO.2007.13. 9626 18268356
19. JD Lamb RL Garcia BA Goff PJ Paley EM Swisher 2006 Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy Am J Obstet Gynecol 194 6 1702 1709 10.1016/j.ajog.2006.03.006 16731090
20. PJ Paley EM Swisher RL Garcia SN Agoff BE Greer KL Peters BA Goff 2001 Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis Gynecol Oncol 80 2 176 180 1:STN:280:DC%2BD3M7ktlCjsg%3D%3D 10.1006/gyno.2000.6071 11161856
21. CB Powell E Kenley LM Chen B Crawford J McLennan C Zaloudek M Komaromy M Beattie J Ziegler 2005 Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J Clin Oncol 23 1 127 132 10.1200/JCO.2005.04.109 15625367
22. A Finch P Shaw B Rosen J Murphy SA Narod TJ Colgan 2006 Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers Gynecol Oncol 100 1 58 64 1:CAS:528:DC%2BD2MXhtlCksbbP 10.1016/j.ygyno.2005.06.065 16137750
23. BB Hermsen PJ van Diest J Berkhof FH Menko JJ Gille JM Piek S Meijer HA Winters P Kenemans SV Mensdorff-Pouilly, et al. 2006 Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer Int J Cancer 119 6 1412 1418 1:CAS:528:DC%2BD28XovVOqs7g%3D 10.1002/ijc.21988 16615107
24. MJ Casey C Synder C Bewtra SA Narod P Watson HT Lynch 2005 Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations Gynecol Oncol 97 2 457 467 10.1016/j.ygyno.2005.01.039 15863145
25. PA Meeuwissen C Seynaeve CT Brekelmans HJ Meijers-Heijboer JG Klijn CW Burger 2005 Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer Gynecol Oncol 97 2 476 482 10.1016/j.ygyno.2005.01.024 15863147
26. MJ Callahan CP Crum F Medeiros DW Kindelberger JA Elvin JE Garber CM Feltmate RS Berkowitz MG Muto 2007 Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J Clin Oncol 25 25 3985 3990 10.1200/JCO.2007.12.2622 17761984
27. K Levanon C Crum R Drapkin 2008 New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 32 5284 5293 10.1200/JCO.2008.18.1107 18854563
28. BY Karlan 2004 Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis Gynecol Oncol 92 2 519 520 10.1016/j.ygyno.2003.12.009 14766241
29. R Eitan R Soslow O Lin ND Kauff L Liu RR Barakat DS Chi 2006 The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy Gynecol Oncol 102 2 315 318 10.1016/j.ygyno.2005.12.021 16430946
30. SN Agoff RL Garcia B Goff E Swisher 2004 Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations Am J Surg Pathol 28 8 1112 1114 10.1097/01.pas.0000131554.05732.cd 15252324
31. JA Villella M Parmar K Donohue C Fahey MS Piver K Rodabaugh 2006 Role of prophylactic hysterectomy in patients at high risk for hereditary cancers Gynecol Oncol 102 3 475 479 10.1016/j.ygyno.2006.01.006 16473397
32. DF Easton D Ford DT Bishop 1995 Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1 265 271 1:STN:280:DyaK2M7is1Whsw%3D%3D 7825587
33. A Antoniou PD Pharoah S Narod HA Risch JE Eyfjord JL Hopper N Loman H Olsson O Johannsson A Borg, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 1117 1130 1:CAS:528:DC%2BD3sXjslagtbg%3D 10.1086/375033 12677558
34. GR Evans KN Gaarenstroom D Stirling A Shenton L Maehle A Dorum M Steel F Lalloo J Apold M Porteous, et al. 2009 Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers J Med Genet 46 9 593 597 1:CAS:528:DC%2BD1MXht1yntr7J 10.1136/jmg.2008.058248 18413372